Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Trial Profile

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Crizotinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Taxanes (Primary)
  • Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CRISP
  • Sponsors AIO Studien gGmbH
  • Most Recent Events

    • 16 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2026.
    • 01 Oct 2022 Results from this and other study assessing the impact of immune checkpoint inhibitors on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cancer, published in the Lung Cancer
    • 13 Sep 2022 Results of an analysis assessing patient reported outcomes and quality of life from a representative advanced non-small cell lung cancer cohort in Germany from this trial presented at the 47th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top